Cognition Therapeutics, Inc. (CGTX) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to Cognition Therapeutics Incorporated's fourth quarter and fiscal year 2022 earnings conference call. My name is Julianne, and I'll be your conference operator today. This call is being recorded. I would like to turn the presentation over now to your host for today's call, Daniel Conte-Boitin, Investor Relations for Cognition Therapeutics. Please go ahead, Mr. Conte-Boitin. Thank you, Julianne. Good morning and thank you for participating in Cognition Therapeutics conference call today. With me today are Lisa O'Shaughnessy, President and Chief Executive Officer of Cognition, and Andrew Einhorn, Interim Chief Financial Officer of Cognition. A press release detailing Cognition Therapeutics 2022 results is available on the investor section of our website at cogrx.com. We encourage everyone to read this morning's press release as well as Cognition's annual report on Form 10-K which is now filed with the SEC and available on our website. In addition, this conference call is being webcast through the company's website and will be archived for 30 days. Please note that certain information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities Litigations Reform Act. We caution listeners that during this call, management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risk and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in Cognition's press releases and SEC filings, including its annual report on Form 10-K and previous filings. This conference call contains time-sensitive information th...